The global radiotheranostics market size was valued at USD 7.5 billion in 2022, driven by the increasing prevalence of cancer across the globe. The market size is anticipated to grow at a CAGR of 13.5% during the forecast period of 2023-2031 to achieve a value of USD 23.5 billion by 2031.
Radiotheranostics is a unique approach where a tiny molecule is used like a double agent. First, it acts as a spy to show where cancer cells are and how many there are (diagnosis). Then, it attaches to these cells and gives them a special kind of treatment using radiation (treatment). Its like using the same tool for finding and attacking the bad cells, all in one go. This way of doing things is like a clever strategy to help treat cancer in a more precise and personalized way.
The rising demand for personalized cancer treatment and medications is a major trend influencing the market growth. The rise in awareness about cancer treatments and evolving therapeutics approaches are all trends contributing to the increased demand for precision medicine, hence boosting the market growth. Increased initiatives by the government to implement regulatory framework towards cancer treatments with radiotheranostics therapeutics is also a major trend influencing the global radiotheranostics market growth.
The increasing number of research and development activities in radiotheranostics are also driving the market growth, for instance the treatment for cancer was a major priority for research in a joint UK-US cancer funding review which happened in March 2023. The increasing popularity of radiopharmaceuticals is also contributing to the rising radiotheranostics market share. For example, USA and Europe have approved radiopharmaceuticals for a targeted α-therapy of non-Hodgkin lymphomas and PSAM-positive prostate carcinoma. The increasing technological developments are also increasing the demand for radiotheranostics.
The continuously advancing imaging technologies, such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI), are also propelling the market growth. The continuous research studies and practices on finding the potential clinical applications of radiotheranostics therapeutics in cancer therapy, neurology, and cardiology are also expected to further escalate the market expansion.
Market Breakup by Radioisotope
Market Breakup by Applications
Market Breakup by Region
The rising prevalence of cancer is the major factor responsible for the market growth. The increase in geriatric population is also a major factor driving the market growth globally. With increasing age body cells gets more prone to mutation resulting in development of cancer cells. The rapid adaptation of sedentary lifestyle is also contributing to the rise in cancer cases worldwide. Along with evolving lifestyles, stress has booked a huge share in such lifestyles, further contributing to rising number of cancer cases as stress is also capable of converting healthy cells into cancer cells.
Due to all the above-mentioned factors, the demand for radiotheranostics therapeutics is on high rise. Due to the targeted diagnosis approach of radiotheranostics therapeutics, it is getting traction from people and healthcare professionals. As radiotheranostics therapeutics works on personalized medicine approaches the scope of nuclear medicine in treating wide range of chronic disorders and a surging trend for precision medicine are anticipated to further propel the global radiotheranostics market growth.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Radioisotope||
|Breakup by Applications||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Radiotheranostics Market Overview
3.1 Global Radiotheranostics Market Historical Value (2016-2022)
3.2 Global Radiotheranostics Market Forecast Value (2023-2031)
4 Global Radiotheranostics Market Landscape
4.1 Global Radiotheranostics: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Radiotheranostics: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Applications
5 Global Radiotheranostics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Radiotheranostics Market Segmentation
6.1 Global Radiotheranostics Market by Radioisotope
6.1.1 Market Overview
6.1.7 18F with Y-90
6.2 Global Radiotheranostics Market by Applications
6.2.1 Market Overview
6.3 Global Radiotheranostics Market by Region
6.3.1 Market Overview
6.3.2 North America
6.3.4 Asia Pacific
6.3.5 Latin America
6.3.6 Middle East and Africa
7 North America Radiotheranostics Market
7.1 Market Share by Country
7.2 United States of America
8 Europe Radiotheranostics Market
8.1 Market Share by Country
8.2 United Kingdom
9 Asia Pacific Radiotheranostics Market
9.1 Market Share by Country
10 Latin America Radiotheranostics Market
10.1 Market Share by Country
11 Middle East and Africa Radiotheranostics Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.5 South Africa
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Novartis AG
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.2 Bayer AG
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.3 Progenics Pharmaceuticals, Inc.(Lantheus)
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.4 Telix Pharmaceuticals Limited.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.5 ITM Radiopharma
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.6 Life Molecular Imaging.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.8 IsoTherapeutics Group, LLC
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.9 Q BioMed Inc.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.10 Nordic Nanovector ASA
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market attained a value of about USD 7.5 billion in 2022, driven by the increasing geriatric population.
The market is anticipated to grow at a CAGR of 13.5% during the forecast period of 2023-2031, likely to reach a market value of USD 23.5 billion by 2031.
The rising geriatric population and increasing prevalence of cancer are among the major factors driving the market growth.
The increasing popularity of radiopharmaceuticals is driving the increase in demand for radiotheranostics therapeutics and increasing number of research and development activities around the world are among major trends influencing the market growth.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.
The radioisotope for radiotheranostics include Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90.
They find wide applications in oncology and non-oncology.
Key players involved in the market are Novartis AG, Bayer AG, Progenics Pharmaceuticals, Inc. (Lantheus), Telix Pharmaceuticals Limited., ITM Radiopharma, Life Molecular Imaging., RadioMedix, IsoTherapeutics Group, LLC, Q BioMed Inc., and Nordic Nanovector ASA.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.